Description
Dopazin-L — A Novel Insulin-Independent Combination Targeting the Root of Type 2 Diabetes
Dopazin-L combines Dapagliflozin 10 mg with Linagliptin 5 mg, bringing together two insulin-independent mechanisms in one tablet. Dapagliflozin lowers blood sugar by helping the body excrete excess glucose through urine, while Linagliptin works by increasing natural substances that lower blood sugar specifically when it’s elevated. This dual approach targets sugar spikes without relying on insulin secretion, making Dopazin-L a relevant option for physicians managing Type 2 Diabetes Mellitus who also want to factor in cardiac risk. With decreased cardiac risk and reliable glycemic control built into its clinical profile, this combination gives franchise partners a genuinely differentiated diabetes molecule to introduce to prescribers.
A Combination That Demands Manufacturing Precision
Lxir Medilabs is an ISO and WHO-GMP certified pharmaceutical company headquartered in Panchkula, Haryana with manufacturing carried out at our Baddi, Himachal Pradesh facility. Combining an SGLT2 inhibitor with a DPP-4 inhibitor in a single tablet requires precise formulation control to keep both actives stable and consistently bioavailable and Dopazin-L is manufactured under strict quality protocols to maintain this reliability across every batch. For a PCD pharma franchise company in India, launching a new insulin-independent combination with cardiac safety considerations gives field partners a strong story for diabetologists and cardiologists alike.
Product Highlights for Franchise Partners
- Composition: Dapagliflozin 10 mg + Linagliptin 5 mg
- Dosage Form: Tablets
- Pack Size: 10 x 10 Tablets
- Indications: Type 2 Diabetes Mellitus, decreased cardiac risk with desired glycemic control
- Key Benefit: A novel insulin-independent anti-diabetic with cardiac safety
- Suited For: Distributors and medical representatives expanding their diabetology range
Franchise partners looking to add a novel insulin-independent diabetes combination to their portfolio can explore this and other formulations through our PCD pharma franchise division, with complete launch support.
Disclaimer: This is a prescription product and should be used strictly under the supervision of a registered medical practitioner.
